Get the Stockscreener App
31.80
3.33%
-1.095
After Hours:
31.80
Atricure Inc stock is traded at $31.80, with a volume of 1.66M.
It is down -3.33% in the last 24 hours and down -15.52% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$32.90
Open:
$33.01
24h Volume:
1.66M
Relative Volume:
3.07
Market Cap:
$1.58B
Revenue:
$499.95M
Net Income/Loss:
$-36.36M
P/E Ratio:
-41.30
EPS:
-0.77
Net Cash Flow:
$24.22M
1W Performance:
-12.15%
1M Performance:
-15.52%
6M Performance:
-11.27%
1Y Performance:
-24.93%
1-Day Range:
$31.17
$33.22
1-Week Range:
$30.47
$38.07
52-Week Range:
$28.29
$43.18
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
31.80 | 1.64B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
478.60 | 176.19B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
177.81 | 51.41B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
78.55 | 39.00B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.59 | 37.48B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
245.73 | 37.82B | 5.40B | 1.49B | 1.78B | 10.12 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure's (ATRC) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Needham Reiterates AtriCure (ATRC) Buy Rating with $45 Price Tar - GuruFocus
Needham reiterates Buy rating on AtriCure stock amid competition By Investing.com - Investing.com India
Needham reiterates Buy rating on AtriCure stock amid competition - Investing.com
AtriCure stock maintains Market Outperform rating at Citizens despite Edwards competition - Investing.com India
(ATRC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JPMorgan downgrades AtriCure stock rating to Neutral on Edwards competition - Investing.com Nigeria
Sector Update: Health Care Stocks Rise Late Afternoon - marketscreener.com
AtriCure (ATRC) Shares Fall 15% Following JPMorgan Downgrade - GuruFocus
AtriCure (NASDAQ:ATRC) Shares Gap Down After Analyst Downgrade - MarketBeat
AtriCure (NASDAQ:ATRC) Rating Lowered to Neutral at JPMorgan Chase & Co. - MarketBeat
JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48 - marketscreener.com
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
AtriCure (ATRC) Projected to Post Earnings on Tuesday - MarketBeat
Profit Review: Is AtriCure Inc a potential multi baggerJuly 2025 News Drivers & Consistent Return Strategy Ideas - baoquankhu1.vn
First Week of March 20th Options Trading For AtriCure (ATRC) - Nasdaq
AtriCure (NASDAQ:ATRC) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Wave Life Sciences (WVE) and Arcellx Inc (ACLX) - The Globe and Mail
AtriCure, Inc. (ATRC) Stock Analysis: A Compelling 43% Upside Potential For Investors - DirectorsTalk Interviews
AtriCure stock maintains Overweight rating at Piper Sandler on BoxX-NoAF potential - Investing.com India
AtriCure stock maintains Overweight rating at Piper Sandler on BoxX-NoAF potential By Investing.com - Investing.com South Africa
(ATRC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Local public company secures incentive for $45M project, likely to create hundreds of jobs - WKRC
Income Plays: Is AtriCure Inc a cyclical or defensive stock2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Weekly Recap: Will ARS Pharmaceuticals Inc announce a stock splitJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Red-hot medical device firm gets big JobsOhio grant for $45M expansion - The Business Journals
Reasons to Retain Avanos Medical Stock in Your Portfolio Now - sharewise.com
When Will AtriCure, Inc. (NASDAQ:ATRC) Turn A Profit? - 富途牛牛
Market Wrap: Does AtriCure Inc have declining or rising EPSJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Riverwater Partners LLC Buys 26,657 Shares of AtriCure, Inc. $ATRC - MarketBeat
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results - Chartmill
The Zacks Analyst Blog Highlights AtriCure, REV Group, Oceaneering International and Analog Devices - Yahoo Finance
Market Pulse: Is AtriCure Inc stock trending bullish2025 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
SG Americas Securities LLC Has $824,000 Position in AtriCure, Inc. $ATRC - MarketBeat
(ATRC) Risk Channels and Responsive Allocation - Stock Traders Daily
AtriCure, Inc. (ATRC) Stock Analysis: A Promising 35% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
AtriCure (ATRC) Is Down 5.8% After Issuing 2026 Profitability Guidance And Expanding Credit Facility - Yahoo Finance
What are AtriCure Incs recent SEC filings showingMarket Growth Review & Long-Term Safe Return Strategies - baoquankhu1.vn
Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results - Prime Publishers, Inc.
AI Diagnostics: The End of the High-Cost Imaging Era - GlobeNewswire
AtriCure Stock (+11%): Profitability Inflection Ignites Re-Rate - Trefis
AtriCure (NASDAQ:ATRC) Trading 6.7% HigherHere's Why - MarketBeat
AtriCure Inc (ATRC) Shares Up 8.49% on Jan 15 - GuruFocus
AtriCure CEO Touts $10B AFib and Pain Market, Raises EBITDA Outlook at JPMorgan Conference - MarketBeat
Momentum Shift: Is AtriCure Inc a potential multi baggerRate Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
ATRC: Innovation and clinical evidence drive growth in AFib and pain management, with strong financial results - TradingView
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Boston Scientific (BSX) - The Globe and Mail
Street Watch: What is AtriCure Incs revenue forecastBear Alert & Low Risk Investment Opportunities - baoquankhu1.vn
AtriCure reports 13% revenue growth in Q4 2025, provides 2026 outlook - Investing.com Nigeria
AtriCure (NASDAQ:ATRC) Shares Down 7.6%Time to Sell? - MarketBeat
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):